Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
| Autor: | Juan Antonio Martell, Beatriz Paredes Moreno, Jorge Luis Soriano, Ivis Mendoza Hernadez, Patricia Lorenzo-Luaces, Mayra Ramos-Suzarte, Jose Alert, Yanela Santiesteban González, Yulainis Santiesteban Gonzalez, Tania Crombet Ramos, Yisel Ávila Albuerne, Erika Ruiz-García, Mayté Lima Pérez, Horacio Astudillo-de la Vega, Idael Pineda Callejo, Carmen Viada González, Eduardo Santiesteban Alvarez, Nery Gonzalez Lazo |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Antibodies Monoclonal Humanized Epidermal growth factor Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans Nimotuzumab Epidermal growth factor receptor Pharmacology Chemotherapy biology business.industry Middle Aged Esophageal cancer medicine.disease Combined Modality Therapy ErbB Receptors Radiation therapy Treatment Outcome biology.protein Molecular Medicine Female business Chemoradiotherapy medicine.drug |
| Zdroj: | Cancer Biology & Therapy. 13:600-605 |
| ISSN: | 1555-8576 1538-4047 |
| DOI: | 10.4161/cbt.19849 |
| Popis: | Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis. The present study was conducted to evaluate safety and preliminary efficacy of nimotuzumab, a humanized anti-EGFR antibody in combination with radiation and chemotherapy in advanced esophageal tumours.A Phase II clinical trial was conducted, where patients received cisplatin, 5-fluorouracil, and radiotherapy, either alone or combined with six weekly infusions of nimotuzumab at the dose of 200 mg. Safety was the primary endpoint. The antitumoral objective response rate was the secondary endpoint. Epidermal growth factor receptor expression, KRAS mutation status and anti-idiotypic response were also evaluated.Sixty-three patients were included in the study. Thirty patients were entered into the control group, and thirty-three patients received the treatment with nimotuzumab. The antibody was very well tolerated. Objective response rate was 47.8 % (nimotuzumab group) and 15.4 % (control group). Disease control rate was 60.9 % (nimotuzumab group) and 26.9 % (control group). Response and disease control rate were higher in patients with EGFR overexpressing tumors.Nimotuzumab plus chemoradiotherapy was safe and provided statistically significant objective response. A Phase III in patients with similar characteristics will be launched. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|